ReviewRSC medicinal chemistry2025
Indazole - an emerging privileged scaffold: synthesis and its biological significance.
Review in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- N-(1H-Indazolyl) Aryl Sulfonamide Hybrids as Potential Dihydropteroate Synthase Inhibitors: In Vitro Antibacterial Activity Against Escherichia coli and Staphylococcus aureus and Computational Modeling.Chemistry & biodiversity · 2026Article
- Exploring Novel Indazole and Pyrazole Nucleoside Analogues: Enzymatic Synthesis, Characterization, and Biological Evaluation.International journal of molecular sciences · 2026Article
- Design, Synthesis, and Biological Evaluation of Tetrahydroindazole-Based Sulfonamides as Potential Multi-Target Anti-Inflammatory Agents.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Molecular Pharmacology at the Crossroads of Precision Medicine.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nitrogen-containing molecules are an important class of heterocyclic compounds. Among these, indazole is one of the most important scaffolds with a broad scope because of its pharmaceutical and biological properties. Many novel molecules were reported in clinical trials for treating various diseases containing the indazole scaffold. Indazole has a vast potential for the discovery of novel pharmaceuticals such as anti-bacterial, anti-fungal, anti-leishmanial, antidiabetic, anti-cancer, anti-tuberculosis, anti-Parkinson's, anti-protozoal, anti-depressant, and anti-inflammatory. This review covers the structures of new indazoles, the current pipeline of indazole-containing compounds in the various stages of clinical trials, and naturally occurring indazoles, along with some marketed drugs. Furthermore, we have covered the different methods for the synthesis of 1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.